Team News Riveting
Mumbai, October 26
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company, has launch a fixed dose combination (FDC) for type 2 diabetes at an affordable price.
The Mumbai-based firm has become the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/ 1000 mg) Fixed Dose Combination (FDC). The FDC will be marketed under two brand names Remo MV and Remozen MV, the company said.
Remogliflozin is an innovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor indicated for the treatment of Type 2 diabetes in adults. With this launch, the company aims to improve patient access to SGLT2 inhibitors and DPP4 inhibitors which have proven benefits in the effective management of diabetes with added advantage of patient compliance.
The Glenmark’s Remo MV and Remozen MV are priced at Rs 16.5 per tab, Rs 33 per day cost of therapy which is 53 per cent lower than the other available SGLT2 & DPP4 combination brands administered along with Metformin, in India.
“Globally, SGLT2i + DPP4i + Metformin FDCs are emerging as a preferred treatment for management of type-2 diabetes. Diabetes is a key focus area for Glenmark and we have been at the forefront in providing access to the latest treatment options to diabetes patients in India. We are proud to introduce this innovative fixed dose combination, which is cutting-edge, extensively researched, at an affordable cost and will significantly improve patient compliance and provide glycemic & extra glycemic benefits to patients with uncontrolled Type 2 diabetes, in India” said Alok Malik, Group Vice President & Business Head, India Formulations.
